Description:
MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.
- Molecular Weight: 448.549
- Molecular Formula: C22H24N8OS
Purity: 98%
Canonical SMILES:
CCC1=CN=C(N=C1)N2CCC(CC2)C3=NC(=CS3)COC4=CC=C(C=C4)N5C=NN=N5
InChI:
InChI=1S/C22H24N8OS/c1-2-16-11-23-22(24-12-16)29-9-7-17(8-10-29)21-26-18(14-32-21)13-31-20-5-3-19(4-6-20)30-15-25-27-28-30/h3-6,11-12,14-15,17H,2,7-10,13H2,1H3
InChIKey: NFTMKHWBOINJGM-UHFFFAOYSA-N
Synonyms:
Pyrimidine, MBX-2982; MBX 2982; MBX2982; SAR-260093; SAR260093; SAR 260093; 5-ethyl-2-(4-(4-((4-(1H-tetrazol-1-yl)phenoxy)methyl)-2-thiazolyl)-1-piperidinyl)-; 4-((4-(1H-tetrazol-1-yl)phenoxy)methyl)-2-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)thiazole; B5TRY67L51
More details are to be found on supplier website
